![Philippe Fauchet](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Philippe Fauchet
Director/Board Member at
REZOLUTE, INC.
Net worth: 162 840 $ as of 2026-07-30
Profile
Philippe Fauchet is currently an Independent Director at Rezolute, Inc. since 2020, an Independent Outside Director at Noile-Immune Biotech, Inc. since 2020, an Outside Director at Luca Science, Inc. since 2022, an Independent Outside Director at JCR Pharmaceuticals Co., Ltd. since 2013, and a Venture Partner & Japana6 at 4BIO Ventures Management Ltd. since 2019.
Former positions include Chairman at GlaxoSmithKline KK from 2018 to 2019 and Senior VP & Head-Corporate Business Development at Sanofi-Aventis Groupe SA. Education includes graduate studies at École des Hautes Études Commerciales de Paris and undergraduate studies at Université Paris Nanterre.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
REZOLUTE, INC. 0.04% | 2025-11-18 | 34,500 ( 0.04% ) | 162 840 $ | 2026-07-30 |
Philippe Fauchet active positions
| Companies | Position | Start |
|---|---|---|
| REZOLUTE, INC. | Director/Board Member | 2020-09-09 |
| NOILE-IMMUNE BIOTECH INC. | Director/Board Member | 2020-02-29 |
| JCR PHARMACEUTICALS CO., LTD. | Director/Board Member | 2013-05-31 |
4BIO Ventures Management Ltd.
 4BIO Ventures Management Ltd. Investment ManagersFinance 4bio Ventures invest in companies located in the United Kingdom. The firm targets the companies operating in the fields of gene therapy, cell theray, RNA based therapy, targeted therapies and microbiome. They provide financing for early stage capital requirements. | Private Equity Investor | 2018-12-31 |
Luca Science, Inc.
 Luca Science, Inc. BiotechnologyHealth Technology Develops mitochondrial transplantation therapy for mitochondrial diseases | Director/Board Member | 2022-05-31 |
Former positions of Philippe Fauchet
| Companies | Position | End |
|---|---|---|
GlaxoSmithKline KK
 GlaxoSmithKline KK Household/Personal CareConsumer Non-Durables Researches, develops, imports, manufactures and sells toiletry products | President | 2018-01-12 |
Sanofi-Aventis Groupe SA
 Sanofi-Aventis Groupe SA Financial ConglomeratesFinance Functions as an investment holding company | Corporate Officer/Principal | - |
Training of Philippe Fauchet
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
52
1st degree connections
9
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
GlaxoSmithKline KK
GlaxoSmithKline KK Household/Personal CareConsumer Non-Durables Researches, develops, imports, manufactures and sells toiletry products | Consumer Non-Durables |
JCR Pharmaceuticals Co., Ltd.
 JCR Pharmaceuticals Co., Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and sells ethical drugs and regenerative medicine | Health Technology |
École des Hautes Études Commerciales de Paris
 École des Hautes Études Commerciales de Paris Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Université Paris Nanterre
 Université Paris Nanterre Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rezolute, Inc.
 Rezolute, Inc. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for metabolic diseases related to chronic glucose imbalance | Health Technology |
Sanofi-Aventis Groupe SA
Sanofi-Aventis Groupe SA Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Noile-Immune Biotech, Inc.
 Noile-Immune Biotech, Inc. Pharmaceuticals: MajorHealth Technology Engages in the development of CAR-T cell therapy based therapeutic cancer drugs | Health Technology |
4BIO Ventures Management Ltd.
4BIO Ventures Management Ltd. Investment ManagersFinance 4bio Ventures invest in companies located in the United Kingdom. The firm targets the companies operating in the fields of gene therapy, cell theray, RNA based therapy, targeted therapies and microbiome. They provide financing for early stage capital requirements. | Finance |
Luca Science, Inc.
Luca Science, Inc. BiotechnologyHealth Technology Develops mitochondrial transplantation therapy for mitochondrial diseases | Health Technology |
- Stock Market
- Insiders
- Philippe Fauchet
